H
Hongchao Pan
Researcher at University of Oxford
Publications - 49
Citations - 12915
Hongchao Pan is an academic researcher from University of Oxford. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 21, co-authored 39 publications receiving 9834 citations. Previous affiliations of Hongchao Pan include Medical Research Council & Clinical Trial Service Unit.
Papers
More filters
Journal ArticleDOI
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Hongchao Pan,Richard Peto,Ana-Maria Henao-Restrepo,Marie-Pierre Preziosi,Vasee Sathiyamoorthy,Quarraisha Abdool Karim,Marissa M. Alejandria,César Hernández García,Marie-Paule Kieny,Reza Malekzadeh,Srinivas Murthy,K. Srinath Reddy,Mirta Roses Periago,Pierre Abi Hanna,Florence Ader,Abdullah M. Al-Bader,Almonther Alhasawi,Emma Allum,Athari Alotaibi,Carlos A Alvarez-Moreno,Sheila Appadoo,Abdullah Asiri,Pål Aukrust,Andreas Barratt-Due,Samir Bellani,Mattia Branca,Heike B. C. Cappel-Porter,Nery Cerrato,Ting S. Chow,Najada Como,Joseph A. Eustace,Patricia J. Garcia,Sheela Godbole,Eduardo Gotuzzo,Laimonas Griskevicius,Rasha Hamra,Mariam Hassan,Mohamed Hassany,David Hutton,Irmansyah Irmansyah,Ligita Jancoriene,Jana Kirwan,Suresh Kumar,Peter Lennon,Gustavo Lopardo,Patrick Lydon,Nicola Magrini,Teresa Maguire,Suzana Manevska,Oriol Manuel,Sibylle McGinty,Marco T. Medina,María L. Mesa Rubio,Maria C. Miranda-Montoya,Jeremy Nel,Estevão Portela Nunes,Markus Perola,Antonio Portolés,Menaldi R. Rasmin,Aun Raza,Helen Rees,Paula P. S. Reges,Chris A Rogers,Kolawole Salami,Marina I. Salvadori,Narvina Sinani,Jonathan A C Sterne,Milena Stevanovikj,Evelina Tacconelli,Kari A.O. Tikkinen,Sven Trelle,Hala Zaid,John-Arne Røttingen,Soumya Swaminathan +73 more
TL;DR: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
Journal ArticleDOI
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
Zhengming Chen,Lixin Jiang,Yiping Chen,J X Xie,Hongchao Pan,Richard Peto,Rory Collins,Lisheng Liu,Commit (ClOpidogrel) +8 more
TL;DR: In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major vascular events in hospital, and should be considered routinely.
Journal ArticleDOI
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Richard Peto,C Davies,Jon Godwin,Richard Gray,Hongchao Pan,Mike Clarke,D Cutter,Sarah C. Darby,Paul McGale,Carolyn W. Taylor,Yixin Wang,Jonas Bergh,A. Di Leo,KS Albain,Sandra M. Swain,M.J. Piccart,Kathleen I. Pritchard +16 more
TL;DR: In meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use.
Journal ArticleDOI
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
C Davies,Hongchao Pan,Jon Godwin,Richard Gray,Rodrigo Arriagada,Vinod Raina,Mirta Abraham,Victor Hugo Medeiros Alencar,Atef Badran,Xavier Bonfill,Joan Caroline Bradbury,Mike Clarke,Rory Collins,Susan R. Davis,Antonella Delmestri,John F. Forbes,Peiman Haddad,Ming-Feng Hou,Moshe Inbar,Hussein M. Khaled,Joanna Kielanowska,Wing-Hong Kwan,Beela Sarah Mathew,Indraneel Mittra,Bettina Muller,Antonio Nicolucci,Octavio Peralta,Fany Pernas,Lubos Petruzelka,Tadeusz Pienkowski,Ramachandran Radhika,Balakrishnan Rajan,Maryna Rubach,Sera Tort,Gerard Urrútia,Miriam Valentini,Yaochen Wang,Richard Peto +37 more
TL;DR: Treatment allocation seemed to have no effect on breast cancer outcome among 1248 women with ER-negative disease, and an intermediate effect among 4800 women with unknown ER status, and a further reduction in recurrence and mortality, particularly after year 10.
Journal ArticleDOI
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan,Richard Gray,Jeremy P Braybrooke,C Davies,Carolyn W. Taylor,Paul McGale,Richard Peto,Kathleen I. Pritchard,Jonas Bergh,Mitch Dowsett,Daniel F. Hayes +10 more
TL;DR: After 5 years of adjuvant endocrine therapy, breast‐cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years, with risks ranging from 10 to 41%, depending on TN status and tumor grade.